Lecanemab (anti-protofibril Aβ MAb) shows modest but statistically significant slowing of cognitive decline (CDR-SB ~0.45 point benefit at 18 months) in early symptomatic AD with PET-confirmed amyloid. First clearly positive Phase III for amyloid-cascade-as-drug-target — confidence updates upward in early-stage AD...

Evidence span

Lecanemab (anti-protofibril Aβ MAb) shows modest but statistically significant slowing of cognitive decline (CDR-SB ~0.45 point benefit at 18 months) in early symptomatic AD with PET-confirmed amyloid. First clearly positive Phase III for amyloid-cascade-as-drug-target — confidence updates upward in early-stage AD...

From Christopher H. van Dyck et al. 2022, New England Journal of Medicine

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

Human, early symptomatic AD (MCI + mild AD dementia) with PET- or CSF-confirmed amyloid; lecanemab 10 mg/kg biweekly IV; n=1795. CLARITY-AD (NCT03887455). 18-month primary endpoint CDR-SB.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required